Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (331-340 of 509) with videos related to

Pageof 51
Sort By:
JAMA Oncology|May 13, 2022
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical TrialPierre Heudel, Jean-Sébastien Frenel, Cécile Dalban, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2015
Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma GroupAxel Le Cesne, Isabelle Ray-Coquard, Florence Duffaud, et al.
Gynecologic Oncology|August 8, 2025
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian DatabaseClaire Chator, Marion Chevrier, Jean-Sébastien Frenel, et al.
Leukemia|April 18, 2024
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancerChristopher Maximilian Arends, Klara Kopp, Raphael Hablesreiter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 11, 2023
Efficacy of chemotherapy according to <i>BRCA</i> status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapseFlora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 21, 2016
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer SurgeryDenis Querleu, François Planchamp, Luis Chiva, et al.
Journal of Adolescent and Young Adult Oncology|November 9, 2019
Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 YearsPerrine Marec-Berard, Valérie Laurence, Bob-Valéry Occean, et al.
Bulletin Du Cancer|October 8, 2023
[Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours]Sabrina Croce, Mojgan Devouassoux-Shisheboran, Patricia Pautier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup studyIgnace B Vergote, Antonio Jimeno, Florence Joly, et al.
Pageof 51

Showing results (331-340 of 509) with videos related to

Sort By:
Pageof 51
JAMA Oncology|May 13, 2022
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical TrialPierre Heudel, Jean-Sébastien Frenel, Cécile Dalban, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2015
Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma GroupAxel Le Cesne, Isabelle Ray-Coquard, Florence Duffaud, et al.
Gynecologic Oncology|August 8, 2025
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian DatabaseClaire Chator, Marion Chevrier, Jean-Sébastien Frenel, et al.
Leukemia|April 18, 2024
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancerChristopher Maximilian Arends, Klara Kopp, Raphael Hablesreiter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 11, 2023
Efficacy of chemotherapy according to <i>BRCA</i> status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapseFlora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 21, 2016
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer SurgeryDenis Querleu, François Planchamp, Luis Chiva, et al.
Journal of Adolescent and Young Adult Oncology|November 9, 2019
Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 YearsPerrine Marec-Berard, Valérie Laurence, Bob-Valéry Occean, et al.
Bulletin Du Cancer|October 8, 2023
[Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours]Sabrina Croce, Mojgan Devouassoux-Shisheboran, Patricia Pautier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup studyIgnace B Vergote, Antonio Jimeno, Florence Joly, et al.
Pageof 51